Using AI to Power Custom Treatments for Rare Diseases with Steven Ringel of Nome Therapeutics 11-10-25

from Becker Private Equity & Business Podcast · host Jeremy Corr

In this episode, Steven Ringel, CEO of the Kizuna Foundation and Nome Therapeutics, joins the podcast to discuss how his team is using artificial intelligence to make personalized medicine accessible for rare disease patients.

Episode metadata supplied by the publisher feed · Published Nov 10, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Using AI to Power Custom Treatments for Rare Diseases with Steven Ringel of Nome Therapeutics 11-10-25

0:00 10:18

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Becker Private Equity & Business Podcast?

This episode is 10 minutes long.

When was this Becker Private Equity & Business Podcast episode published?

This episode was published on November 10, 2025.

Can I download this Becker Private Equity & Business Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!